Saxenda is the brand name for liraglutide, a daily injectable GLP-1 receptor agonist made by Novo Nordisk and FDA-approved for chronic weight management in adults and in adolescents aged 12 and older with obesity. Liraglutide first reached the market in 2010 as Victoza, a lower-dose version approved for type 2 diabetes; Saxenda uses a higher 3 mg daily dose specifically labeled for weight loss. Xultophy combines liraglutide with the long-acting insulin degludec for diabetes. All three share the same active ingredient but carry different FDA labels, doses, and insurance rules.
Novo Nordisk's 2026 list price for a Saxenda carton is approximately $1,349 per month, and cash prices at major pharmacy chains run $1,300 to $1,800 depending on location and dosage strength during the titration schedule. Teva Pharmaceuticals changed the cost picture in August 2025 by launching the first FDA-approved generic liraglutide injection specifically indicated for weight loss, undercutting brand Saxenda by roughly 40 to 70 percent at cash-pay pharmacies. Patients weighing Saxenda against newer options should also compare Wegovy and Zepbound, which are dosed weekly instead of daily and generally produce more weight loss in clinical trials, though at a higher price with no generic yet available.
Medicare classifies Saxenda under the Part D statutory exclusion for weight-loss drugs, and that exclusion has not changed for 2026. The Medicare GLP-1 Bridge demonstration, a short-term CMS program running from July 1, 2026 through December 31, 2027, extends limited coverage to Wegovy and Zepbound for beneficiaries who meet specific BMI and comorbidity criteria, but the program explicitly does not include Saxenda. Medicare beneficiaries who want liraglutide-based weight-loss treatment in 2026 either pay cash for Saxenda or the new generic, or ask their prescriber about a Bridge-eligible alternative.
What Saxenda Costs by Point of Pay (2026)
The price you pay depends almost entirely on WHERE you pay. The same saxenda can cost many times more at a hospital than at your local pharmacy:
2026 Saxenda Price by Point of Pay| Where you pay | Typical cost | Notes |
|---|
| Pharmacy counter (retail, cash, brand) | $1,300 - $1,800/month (2026) | Five-pen carton at full-dose titration. Generic liraglutide runs $400-$800/month with a coupon. |
| Medicare Part D (2026) | Not covered (statutory weight-loss exclusion) | The 2026 Medicare GLP-1 Bridge program covers Wegovy and Zepbound but not Saxenda. |
| Commercial insurance | $25 - $100/month if covered | Requires prior authorization and BMI documentation; many employer plans exclude anti-obesity drugs entirely. |
| Novo Nordisk Patient Assistance Program | $0/month for eligible patients | Free Saxenda for uninsured patients at or below 400% of the federal poverty level in 2026. |
| Medicaid | $1 - $4/prescription, in covering states | Coverage of anti-obesity medications varies widely by state; many states still exclude the category. |
Retail prices reflect 2026 GoodRx and chain pharmacy survey data. Generic liraglutide launched in August 2025 and prices continue to shift as more manufacturers enter the market.
Source: CMS Medicare GLP-1 Bridge program guidance, Novo Nordisk NovoCare, GoodRx, FDA Drugs@FDA
Why Hospitals Charge So Much
Saxenda is a self-injected outpatient prescription drug, so it rarely appears on a hospital bill. When it does, usually because a patient's home supply was administered during an inpatient stay or a hospital pharmacy dispensed a partial carton, the facility charge can run several times the retail cash price. Hospitals typically layer pharmacy handling fees, nursing administration charges, and general facility overhead on top of the drug's acquisition cost, the same pattern seen with Ozempic and other self-administered GLP-1 pens.
Patients who see Saxenda billed at $2,600 or more for a partial carton should request an itemized bill and the National Drug Code (NDC) for the specific product dispensed. The 2026 wholesale acquisition cost for a Saxenda carton is roughly $1,350; inpatient facility charges above $2,600 to $5,200 usually reflect markup layers rather than the drug's real cost. Most commercial insurers and Medicare Part A pay only the negotiated outpatient-equivalent rate, leaving any markup above that as a target for dispute through the hospital's billing office.
Patient Assistance Programs
Novo Nordisk, the manufacturer of Saxenda, offers a patient assistance program for uninsured and underinsured patients. Novo Nordisk discontinued the Saxenda Savings Card for new enrollees on June 30, 2023, so the manufacturer coupon route that once capped commercial copays at $25 per month is no longer available to new patients. The income-based patient assistance program is now the primary manufacturer resource.
Patient assistance programs for Saxenda| Manufacturer program | Cost / Benefit | How to apply |
|---|
| Novo Nordisk Patient Assistance Program (NovoCare) | Free Saxenda for uninsured or underinsured patients at or below 400% of the federal poverty level | novocare.com |
| NeedyMeds Drug Discount Card | Variable discount on Saxenda and generic liraglutide accepted at most US pharmacies | needymeds.org |
| GoodRx / SingleCare discount coupons | Free coupons that can lower generic liraglutide to $400-$800/month at participating pharmacies | goodrx.com |
Manufacturer copay cards, including the discontinued Saxenda Savings Card, were never available to patients on Medicare, Medicaid, TRICARE, or VA benefits under the federal anti-kickback statute (42 U.S.C. § 1320a-7b). If you have government insurance, the Novo Nordisk Patient Assistance Program is the manufacturer-approved path to free medication rather than any commercial coupon.
Source: Novo Nordisk NovoCare patient program pages, NeedyMeds.org, GoodRx
Medicare Part D
Federal law (Section 1860D-2(e)(2) of the Social Security Act) bars Medicare Part D plans from covering drugs used for weight loss. Saxenda's only FDA-approved indication is chronic weight management, so it falls squarely inside that exclusion with no pathway around it. Unlike Wegovy, which CMS said in 2024 could be covered when prescribed to reduce cardiovascular events in patients with established heart disease and obesity, Saxenda carries no additional label that would let a Part D plan pay for it.
CMS launched the Medicare GLP-1 Bridge demonstration on July 1, 2026, running through December 31, 2027, to give eligible beneficiaries limited access to certain GLP-1 drugs at a $50 monthly copay. The Bridge covers Wegovy and Zepbound formulations for beneficiaries meeting BMI or cardiometabolic comorbidity thresholds, but CMS's covered-drug list for the Bridge does not include Saxenda. Medicare beneficiaries interested in liraglutide-based weight-loss therapy should ask their prescriber whether a Bridge-covered alternative fits their clinical profile, since Saxenda itself will not be reimbursed through Original Medicare, Part D, or the Bridge in 2026.
Medicare beneficiaries who are also prescribed liraglutide for type 2 diabetes under the Victoza label, rather than Saxenda's weight-loss label, are covered under standard Part D rules and subject to the general 2026 annual out-of-pocket cap of $2,100 across all Part D drugs combined. The prescription and diagnosis code on file with the pharmacy, not the molecule itself, determine whether a claim processes as a covered diabetes drug or a rejected weight-loss claim.
Common Saxenda Billing Errors
If you were billed for Saxenda above $1,800 with no insurance, or your Medicare claim was rejected unexpectedly, check for these issues before paying:
- Pharmacy dispensed brand Saxenda instead of Teva's generic liraglutide injection without informing you, even though the generic is therapeutically equivalent and often 40 to 70 percent cheaper.
- Claim submitted with a weight-loss diagnosis code when the prescriber intended a diabetes indication (Victoza), or vice versa, causing an automatic Part D rejection.
- Pharmacy attempted to apply the discontinued Saxenda Savings Card, which stopped accepting new enrollees in June 2023, resulting in a claim denial the patient didn't expect.
- Medicare claim incorrectly processed through the GLP-1 Bridge program, which does not cover Saxenda; only Wegovy and Zepbound formulations qualify under the Bridge's 2026 covered-drug list.
- Inpatient hospital charge for a Saxenda dose marked up to several thousand dollars when the retail cash price for a full carton is $1,300 to $1,800.
Frequently Asked Questions
Is there a generic for Saxenda?
Yes. Teva Pharmaceuticals launched an FDA-approved generic liraglutide injection in August 2025, the first generic GLP-1 drug indicated specifically for weight loss. It uses the same active ingredient and dose as Saxenda and typically costs 40 to 70 percent less at cash-pay pharmacies, running roughly $400 to $800 per month with a GoodRx or SingleCare coupon compared to $1,300 to $1,800 for brand Saxenda in 2026.
How do I apply for the Novo Nordisk Patient Assistance Program for Saxenda?
Visit novocare.com or call 1-866-310-7549 to request the Patient Enrollment Form. Complete the patient and prescriber sections, gather proof of income, US residency, and your Saxenda prescription, then submit by fax, mail, or the online portal. Processing takes 7 to 14 business days. If approved, Novo Nordisk ships free Saxenda to your home or prescriber's office, with annual renewal required.
Can I use the Saxenda savings card with Medicare?
No, and the Saxenda Savings Card itself was discontinued for new enrollees in June 2023. Even when it was active, federal anti-kickback law barred anyone on Medicare, Medicaid, TRICARE, or VA benefits from using a manufacturer copay card. If you have government insurance, the Novo Nordisk Patient Assistance Program is the correct path to free or reduced-cost Saxenda instead of any commercial coupon.
What if my insurance denies coverage for Saxenda?
Request the written denial notice, then have your prescriber submit a prior authorization or medical necessity letter documenting your BMI and weight-related health conditions. File a formal appeal within your plan's deadline, and escalate to external review through your state's Department of Insurance if denied again. Meanwhile, ask about generic liraglutide, which is often approved more easily and costs far less than brand Saxenda.
Does the IRA negotiated Medicare price apply to Saxenda?
No. Saxenda is not among the first 10 drugs with a Maximum Fair Price negotiated under the Inflation Reduction Act (effective 2026), and it was not selected for the second negotiation round either, which focuses on semaglutide products like Ozempic and Wegovy. More fundamentally, Medicare Part D does not cover Saxenda at all because of the statutory weight-loss drug exclusion, so no Maximum Fair Price or formulary tier applies, and the general 2026 Part D $2,100 annual out-of-pocket cap never comes into play for this drug.
What does Saxenda cost without insurance at the pharmacy counter in 2026?
Brand Saxenda costs $1,300 to $1,800 for a 30-day, five-pen carton without insurance in 2026, with prices around $1,656 at Walmart and $1,550 at Costco. Generic liraglutide, available since August 2025, typically costs $400 to $800 per month with a free GoodRx or SingleCare coupon at pharmacies like CVS and Walgreens.
Do I qualify for the Novo Nordisk Patient Assistance Program?
You generally qualify if you are uninsured or underinsured, are a US resident, have a valid Saxenda prescription, and your household income is at or below 400 percent of the federal poverty level in 2026, which is $63,840 for a single person or $132,000 for a family of four. Applicants with existing prescription drug coverage that includes Saxenda typically do not qualify.
Saxenda vs Wegovy: what's the difference?
Both are made by Novo Nordisk, but Saxenda is liraglutide injected once daily and Wegovy is semaglutide injected once weekly. Clinical trials generally show Wegovy produces greater average weight loss than Saxenda. Saxenda now has a much cheaper FDA-approved generic (since August 2025), while Wegovy has no generic and remains far more expensive, though Wegovy has narrow Medicare Part D coverage for cardiovascular risk reduction and Bridge program eligibility that Saxenda lacks entirely.
